The company sources drug substances for Sephience from two third-party manufacturers and contracts two separate manufacturers for bulk drug product. For Translarna, it relies on a single source for some raw materials, two third-party manufacturers for drug substance, two manufacturers for bulk drug product, and three manufacturers capable of packaging services. Vatiquinone raw materials are obtained from one source, with one third-party manufacturer supplying the drug substance and one manufacturer providing bulk drug product. Emflaza drug substance is supplied by a single qualified third-party manufacturer in the U.S., while drug product manufacturing and packaging are conducted under two exclusive supply agreements acquired with Emflaza. These agreements include automatic renewal provisions and royalty payments based on U.S. net sales of the suspension product. The company has contingency plans to seek alternative manufacturers if current suppliers become unavailable; however, delays in supply or clinical trials may occur. Insufficient supply of Emflaza could adversely affect sales, marketing authorization, and commercialization, impacting the company's business and financial results.
Ptc Therapeutics Inc's Comment on Supply Chain
The company sources drug substances for Sephience from two third-party manufacturers and contracts two separate manufacturers for bulk drug product. For Translarna, it relies on a single source for some raw materials, two third-party manufacturers for drug substance, two manufacturers for bulk drug product, and three manufacturers capable of packaging services. Vatiquinone raw materials are obtained from one source, with one third-party manufacturer supplying the drug substance and one manufacturer providing bulk drug product. Emflaza drug substance is supplied by a single qualified third-party manufacturer in the U.S., while drug product manufacturing and packaging are conducted under two exclusive supply agreements acquired with Emflaza. These agreements include automatic renewal provisions and royalty payments based on U.S. net sales of the suspension product. The company has contingency plans to seek alternative manufacturers if current suppliers become unavailable; however, delays in supply or clinical trials may occur. Insufficient supply of Emflaza could adversely affect sales, marketing authorization, and commercialization, impacting the company's business and financial results.
Sources:
Ptc Therapeutics inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Ptc Therapeutics inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
